Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/181354 |
Resumo: | Background: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication. Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score. Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well- tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%). Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications. |
id |
UFRGS-2_5192b4ebbbbb7ce497c13ad3c81a637b |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/181354 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Louzã, Mário RodriguesElkis, HelioRuschel, SandraOliveira, Irismar Reis deBressan, Rodrigo AffonsecaBelmonte-de-Abreu, Paulo SilvaGrabowski, Hamilton MiguelAppolinário, José Carlos2018-08-24T02:29:07Z20111178-2021http://hdl.handle.net/10183/181354000855851Background: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication. Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score. Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well- tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%). Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications.application/pdfengNeuropsychiatric disease and treatment. Auckland. Vol. 7, no. 1 (2011), p. 391-398Cooperação do pacienteRisperidonaPreparações de ação retardadaEsquizofreniaPatient complianceAdherenceRisperidoneDelayed-action preparationsSchizophreniaLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophreniaEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000855851.pdfTexto completo (inglês)application/pdf193253http://www.lume.ufrgs.br/bitstream/10183/181354/1/000855851.pdf4e49872d227eb38800b90be93a6835bbMD51TEXT000855851.pdf.txt000855851.pdf.txtExtracted Texttext/plain36979http://www.lume.ufrgs.br/bitstream/10183/181354/2/000855851.pdf.txt69a9edb965b091bbd81b927840bc0049MD52THUMBNAIL000855851.pdf.jpg000855851.pdf.jpgGenerated Thumbnailimage/jpeg1806http://www.lume.ufrgs.br/bitstream/10183/181354/3/000855851.pdf.jpg9e2600baf9dfb6aa4081c73e6f00bfbdMD5310183/1813542018-10-05 07:42:10.797oai:www.lume.ufrgs.br:10183/181354Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2018-10-05T10:42:10Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
spellingShingle |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia Louzã, Mário Rodrigues Cooperação do paciente Risperidona Preparações de ação retardada Esquizofrenia Patient compliance Adherence Risperidone Delayed-action preparations Schizophrenia |
title_short |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_full |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_fullStr |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_full_unstemmed |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
title_sort |
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia |
author |
Louzã, Mário Rodrigues |
author_facet |
Louzã, Mário Rodrigues Elkis, Helio Ruschel, Sandra Oliveira, Irismar Reis de Bressan, Rodrigo Affonseca Belmonte-de-Abreu, Paulo Silva Grabowski, Hamilton Miguel Appolinário, José Carlos |
author_role |
author |
author2 |
Elkis, Helio Ruschel, Sandra Oliveira, Irismar Reis de Bressan, Rodrigo Affonseca Belmonte-de-Abreu, Paulo Silva Grabowski, Hamilton Miguel Appolinário, José Carlos |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Louzã, Mário Rodrigues Elkis, Helio Ruschel, Sandra Oliveira, Irismar Reis de Bressan, Rodrigo Affonseca Belmonte-de-Abreu, Paulo Silva Grabowski, Hamilton Miguel Appolinário, José Carlos |
dc.subject.por.fl_str_mv |
Cooperação do paciente Risperidona Preparações de ação retardada Esquizofrenia |
topic |
Cooperação do paciente Risperidona Preparações de ação retardada Esquizofrenia Patient compliance Adherence Risperidone Delayed-action preparations Schizophrenia |
dc.subject.eng.fl_str_mv |
Patient compliance Adherence Risperidone Delayed-action preparations Schizophrenia |
description |
Background: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication. Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score. Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well- tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%). Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications. |
publishDate |
2011 |
dc.date.issued.fl_str_mv |
2011 |
dc.date.accessioned.fl_str_mv |
2018-08-24T02:29:07Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/181354 |
dc.identifier.issn.pt_BR.fl_str_mv |
1178-2021 |
dc.identifier.nrb.pt_BR.fl_str_mv |
000855851 |
identifier_str_mv |
1178-2021 000855851 |
url |
http://hdl.handle.net/10183/181354 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Neuropsychiatric disease and treatment. Auckland. Vol. 7, no. 1 (2011), p. 391-398 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/181354/1/000855851.pdf http://www.lume.ufrgs.br/bitstream/10183/181354/2/000855851.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/181354/3/000855851.pdf.jpg |
bitstream.checksum.fl_str_mv |
4e49872d227eb38800b90be93a6835bb 69a9edb965b091bbd81b927840bc0049 9e2600baf9dfb6aa4081c73e6f00bfbd |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224949152612352 |